Status:
COMPLETED
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HPV Infections
Eligibility:
FEMALE
9-17 years
Phase:
PHASE2
Brief Summary
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
Eligibility Criteria
Inclusion
- Virginal Female Subject Aged 9 To 17 Years
Exclusion
- Male Subject
Key Trial Info
Start Date :
December 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 18 2009
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT00411749
Start Date
December 11 2006
End Date
September 18 2009
Last Update
April 21 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.